Moderna and Merck: mRNA cancer vaccine cut death and recurrence by 42%
Moderna and Merck said their personalized mRNA cancer vaccine reduced death and recurrence by 42% in melanoma patients. The announcement marks a significant step for mRNA-based cancer treatments.
